The differential effect of illicit drug use on cognitive function in first-episode psychosis and healthy controls

Acta Psychiatrica Scandinavica

Volumn 125, Issue 5, 2012, Pages 400-411

  Donoghue, K ^a   Mazzoncini, R ^b   Hart, J ^c   Zanelli, J ^c   Morgan, C ^c   Dazzan, P ^c   Morgan, K D ^d   Murray, R M ^c   Jones, P B ^e   Doody, G A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF WESTMINSTER   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Drug usage; Neuropsychological tests; Psychotic disorders

Indexed keywords

ILLICIT DRUG; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DISSOCIATIVE DISORDER; DRUG MISUSE; EDUCATIONAL STATUS; ETHNICITY; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PERCEPTION DISORDER; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; UNITED KINGDOM; WORKING MEMORY;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; STREET DRUGS;

EID: 84859823296     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2011.01803.x     Document Type: Article

References (64)

1. Heinrichs RW, Zakzanis KK. Neurocognitive deficits in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-445.
2. Kravariti E, Morgan K, Fearon P et al. Neuropsychological functioning in first-episode schizophrenia. Br J Psychiatry 2009;195:336-345.
3. Dazzan P, Lloyd T, Morgan KD et al. Neurological abnormalities and cognitive ability in first-episode psychosis. Br J Psychiatry 2008;193(3):197-202.
4. Zanelli J, Reichenberg A, Morgan K et al. Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry 2010;167:78-85.
5. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regards to attention, memory and executive functions. Pharmacol Biochem Behav 2005;81:319-330.
6. Barnes TRE, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006;188:237-242.
7. Di Forti M, Morgan C, Dazzan P et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009;195:488-491.
8. Mazzoncini R, Donoghue K, Hart J et al. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr Scand 2010;121:351-358.
9. Yücel M, Bora E, Lubman DI et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2010; doi:10.1093/schbul/sbq079. Accessed July 29 2010.
10. Potvin S, Joyal CC, Pelletier J, Stip E. Contradictory cognitive capacities among substance abusing patients with schizophrenia: a meta-analysis. Schizophr Res 2008;100:242-251.
11. World Health Organization. International Statistical Classification of Diseases, 10th Revision (ICD-10). Geneva, Switzerland: World Health Organization, 1992.
12. Cooper JE, Goodhead D, Craig T, Harris M, Howat J, Korer J. The incidence of schizophrenia in Nottingham. Br J Psychiatry 1987;151:619-626.
13. Fearon P, Kirkbride JB, Morgan C et al. Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC ÆSOP study. Psychol Med 2006;36:1541-1550.
14. Kirkbride JB, Fearon P, Morgan C et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center ÆSOP study. Arch Gen Psychiatry 2006;63:250-258.
15. Jenkins R, Meltzer H. The national survey of psychiatric morbidity In Great Britain. Soc Psychiatry Psychiatr Epidemiol 1995;30:1-4.
16. World Health Organization. Schedules for Clinical Assessment in Neuropsychiatry. Geneva, Switzerland: World Health Organization, 1994.
17. Bebbington PE, Nayani T et al. The psychosis screening questionnaire. J. Methods Psychiatr Res 1995;5:11-19.
18. Jablensky A, Sartorius N, Ernberg G. Schizophrenia: manifestations, incidence, and course in different cultures - a world health organisation ten-country study. Psychol Med Monogr Suppl 1992;20:1-97.
19. Morgan C, Fearon P, Hutchinson G et al. Duration of untreated psychosis and ethnicity in the ÆSOP first-onset psychosis study. Psychol Med 2006;36:239-247.
20. Demjaha A, Morgan K, Morgan C et al. Combining dimensional and categorical representation of psychosis: the way forward for DSM-IV and ICD-11? Psychol Med 2009;39:1943-1955.
21. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.
22. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jørgensen GA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009;9, Available from [8 September 2010].
23. Nelson HE, Willison JR. National Adult Reading Test (part II) Test Manual. Windsor: NFER-Nelson, 1991.
24. Wechsler D. The Wechsler Adult Intelligence Scale-Revised manual. New York: The Psychological Corporation, 1981.
25. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms and Commentary. Oxford: Oxford University Press, 1991.
26. Yeudall LT, Fromm D, Reddon JR, Stefanyk WO. Normative data stratified by age and sex for 12 neuropsychological tests. J Clin Psychol 1986;42:918-946.
27. Reitan R. Validity of the trail making test as an indicator or organic brain damage. Percept Mot Skills 1958;8:271-276.
28. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR. Auditory working memory and Wisconsin card sorting test performance in schizophrenia. Arch Gen Psychiatry 1997;54:159-165.
29. Wechsler D. Wechsler Memory Scale-Revised Manual. New York: The Psychological Corporation, 1987.
30. Faul F. G*Power 3: a flexible statistical power analysis program for the social, behavioural and biomedical sciences. Behav Res Methods 2007;39:175-191.
31. PASW FOR WINDOWS, Rel. 18.0 2009. Chicago: SPSS Inc, 2009.
32. Addington J, Addington D. Substance abuse and cognitive functioning in schizophrenia. J Psychiatry Neurosci 1997;22:99-104.
33. Harrison I, Joyce EM, Mutsatsa SH et al. Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol Med 2008;38:79-88.
34. Rodriguez-Jimenez R, Aragües M, Jimenez-Arriero MA et al. Psychopathology and Wisconsin card sorting test performance in male schizophrenic patients: influence of dual diagnosis. Psychopathology 2008;41:58-64.
35. Derosse P, Kaplan A, Burdick KE, Lencz T, Malhotra AK. Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res 2010;120:95-100.
36. Herman M. Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. Int J Ment Health Nurs 2004;13:282-291.
37. Potvin S, Pampoulova T, Lipp O, Bentaleb LA, Lalonde P, Stip E. Working memory and depressive symptoms in patients with schizophrenia and substance use disorders. Cogn Neuropsychiatry 2008;13:357-366.
38. Carey KB, Carey MP, Simons JS. Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J Nerv Ment Dis 2003;191:300-308.
39. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991;148:224-230.
40. Arndt S, Tyrrell G, Flaum M, Andreasen NC. Comorbidity of substance abuse and schizophrenia: the role of premorbid adjustment. Psychol Med 1992;22:379-388.
41. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis. Arch Gen Psychiatry 1982;39:141-147.
42. Leeson VC, Harrison I, Ron MA, Barnes TRE, Joyce EM. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull 2011; doi:. Accessed 10 August 2011.
43. Sevy S, Robinson DG, Holloway S et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001;104:367-374.
44. Mccleery A, Addington J, Addington D. Substance misuse and cognitive functioning in early psychosis: a 2year follow-up. Schizophr Res 2006;88:187-191.
45. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003;28:48-54.
46. Verrico CD, Jentsch JD, Roth RH. Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 2003;49:61-66.
47. Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 2005;26:480-492.
48. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage 2004;23:914-920.
49. Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology 2004;176:239-247.
50. Solowij N, Battisti RA. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 2008;1:81-98.
51. Mchale S, Hunt N. Executive function deficits in short-term abstinent cannabis users. Hum Psychopharmacol 2008;23:409-415.
52. Jockers-Scherübl MC, Wolf T, Radzei N et al. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol 2007;31:1054-1063.
53. Scholes KE, Martin-Iverson MT. Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychol Med 2010;40:1635-1646.
54. Coulston CM, Perdices M, Tennant CC. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use and recency of use. Schizophr Res 2007;96:169-184.
55. Coulston CM, Perdices M, Henderson AE, Malhi GS. Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use. Schizophr Res Treatment 2010. Available from Accessed 10 January 2011.
56. Cohen M, Solowij N, Carr V. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust N Z J Psychiatry 2008;42:357-368.
57. Schnell T, Koethe D, Daumann J, Gouzoulis-Mayfrank E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology 2009;205:45-52.
58. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002;59:1337-1343.
59. Martin G, Wilkinson A, Kapur B. Validation of self-reported cannabis use by urine analysis. Addict Behav 1988;13:147-150.
60. Kedzior K, Badcock J, Martin-Ivorson M. Validity and consistency of self-reports regarding substance use in general research volunteers, including regular cannabis users and schizophrenia patients. Subst Use Misuse 2006;41:743-750.
61. Beatty WW, Katzung VM, Moreland VJ, Nixon SJ. Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend 1995;37:247-253.
62. Defranco C, Tarbox AR, Mclaughlin EJ. Cognitive deficits as a function of years of alcohol abuse. Am J Drug Alcohol Abuse 1985;11:279-293.
63. Gurling HM, Curtis D, Murray RM. Psychological deficits from excessive alcohol consumption: evidence from a co-twin control study. Br J Addict 1991;86:151-155.
64. Coulston CM, Perdices M, Tennant CC. The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. Aust N Z J Psychiatry 2007;41:869-884.